This Week in Nephrology — Jun 14, 2026

Welcome to This Week in Nephrology. This week we're covering 7 notable papers spanning advances in kidney transplantation and new perspectives on chronic kidney disease, from risk factors to new therapeutics and diagnostics. Let's dive in.

We begin this week in the field of transplantation, where three new papers offer insights into monitoring for rejection and understanding the long-term consequences of immunosuppression. A major challenge in post-transplant care is the non-invasive diagnosis of rejection. Two papers in the American Journal of Transplantation tackle this from different angles. First, a study by Benning and colleagues addresses the limitations of donor-derived cell-free DNA, or dd-cfDNA [5]. While this biomarker is widely used, its low positive predictive value has been a persistent issue. The authors hypothesized that combining the two common ways of reporting dd-cfDNA — as a percentage of total cell-free DNA and as absolute copies per milliliter — could improve accuracy. They developed a composite score, called the CM-Score, and validated it across five independent cohorts. The results were compelling. While maintaining a high negative predictive value of 91 percent, the composite score significantly improved the positive predictive value for rejection to 81 percent, a substantial increase from the roughly 54 percent seen in published data. For the practicing clinician, this composite score offers a more robust tool, providing greater confidence when a high dd-cfDNA value suggests rejection and potentially avoiding unnecessary biopsies. Also in the American Journal of Transplantation, Butler and colleagues explored the role of non-HLA antibodies in kidney allograft rejection [7]. Using protein microarray analysis, they identified 12 novel non-HLA antigens and developed a Luminex assay to test for antibodies against these and other previously reported antigens. In validation cohorts of both adult and pediatric transplant recipients, they found that several non-HLA antibodies were associated with rejection. Four antibodies in particular — against PLA2R1, CSF2, GSTT1, and LGALS8 — were independently associated with rejection. Notably, antibodies against CSF2 were linked to specific histologic findings of acute peritubular capillaritis and intimal arteritis. These findings underscore the growing importance of the non-HLA antibody response and point toward a future where multi-marker assays could better stratify rejection risk. Shifting from rejection diagnostics to the chronic effects of our therapies, a study in Nephrology, Dialysis, Transplantation by Su and colleagues examined the specific histological lesions caused by cyclosporine versus tacrolimus [6]. In a detailed analysis of biopsies from patients with proven calcineurin inhibitor nephrotoxicity, they found distinct patterns of injury. Tacrolimus-associated toxicity was more prominent in the glomerular filtration barrier and interstitial microvasculature, with a tendency toward glomerular scarring. In contrast, cyclosporine had a more severe effect on the proximal tubules, impairing the autophagic-lysosomal pathway and increasing expression of KIM-1. This work provides a high-resolution map of drug-specific injury patterns, which could help refine biopsy interpretation and potentially guide therapeutic choices in the long-term management of transplant recipients.

Our second major theme this week is a series of papers offering new perspectives on chronic kidney disease, covering novel risk factors, treatments, and measurement tools. First, in the Clinical Journal of the American Society of Nephrology, Kim and colleagues investigated the link between clonal hematopoiesis of indeterminate potential, or CHIP, and kidney disease progression [3]. CHIP is an age-related condition where hematopoietic stem cells acquire mutations, leading to a state of chronic inflammation. The study found that the prevalence of CHIP was significantly higher in a Korean CKD cohort compared to healthy controls, at 17 percent versus 11 percent. More importantly, after adjusting for other factors, the presence of CHIP was associated with a nearly doubled risk of progressing to kidney failure. To confirm these findings were not limited to one population, the researchers replicated the analysis in the United Kingdom Biobank, where they observed a similar, roughly two-fold increase in risk. This cross-ethnic validation establishes CHIP as a globally relevant and independent risk factor for CKD progression. From a common, acquired risk factor, we turn to a rare inherited one. A report in Kidney International Reports from Inoki and colleagues sheds new light on the genetics of inherited Fanconi renotubular syndrome [1]. In a cohort of 20 families, genetic testing identified a pathogenic variant in 65 percent of cases. Strikingly, variants in the gene HNF4A were unexpectedly prevalent, accounting for 7 of the 13 identified genetic causes. The study revealed that HNF4A-associated disease often presents as an incomplete Fanconi syndrome and follows a progressive course, with a median kidney survival age of just under 52 years. The clinical takeaway is that HNF4A variants should be considered in patients with incomplete proximal tubular abnormalities or unexplained chronic kidney disease, as this represents an under-recognized and progressive tubulopathy. Alongside identifying causes of CKD, we also have new data on the safety of emerging treatments. A substudy from the ENVISION trial, published in the Clinical Journal of the American Society of Nephrology, examined the humoral response to COVID-19 in patients with IgA nephropathy being treated with sibeprenlimab, an inhibitor of A PRoliferation-Inducing Ligand, or APRIL [4]. A key question for this novel therapy is whether it induces clinically significant immunosuppression. The substudy found that the incidence of symptomatic COVID-19 was comparable between the sibeprenlimab and placebo groups. Furthermore, antibody responses to both vaccination and natural infection were preserved. All vaccinated patients mounted a protective IgG response, and even mucosal immunity, evidenced by salivary IgA, appeared intact. While the authors appropriately caution that this was a small, exploratory analysis, the data are reassuring, suggesting that targeted APRIL inhibition may reduce pathogenic IgA without causing broad impairment of protective immunity. Finally, we end with a paper that revisits a fundamental tool in our specialty: the estimation of GFR. Also in the Clinical Journal of the American Society of Nephrology, Fukae and colleagues evaluated a novel method using d-amino acids — specifically d-serine and d-asparagine [8]. These rare amino acids have ideal clearance characteristics with minimal influence from body size. The researchers developed a GFR estimation formula based on blood levels of these two markers in a cohort of Japanese kidney donors and recipients. The performance of the new equation was equivalent to standard creatinine-based formulas. The critical advantage, however, was that the d-amino acid-based model achieved this accuracy with minimal dependence on demographic variables; age did not significantly improve the model's performance, and the impact of sex was minor. This suggests that d-amino acids could form the basis of a more stable and universally applicable GFR estimation tool, particularly in populations where creatinine-based equations are less reliable, such as in pediatric and elderly patients.

If you only have time for one paper this week, make it the study by Benning and colleagues in the American Journal of Transplantation on the composite score for donor-derived cell-free DNA [5]. This paper offers a practical, readily implementable solution to a common clinical problem — the low positive predictive value of dd-cfDNA testing — and has the potential to immediately improve decision-making in post-transplant monitoring.

Here are the key takeaways from this week in Nephrology: First, in kidney transplantation, combining the percentage and absolute copy number of donor-derived cell-free DNA into a composite score can significantly improve the test's positive predictive value for rejection, giving you more confidence in your non-invasive monitoring. Second, clonal hematopoiesis of indeterminate potential, or CHIP, is an independent risk factor for progression to kidney failure. This association has now been consistently observed in both East Asian and European cohorts, establishing it as a globally relevant risk factor. Third, in patients presenting with incomplete Fanconi syndrome or unexplained chronic kidney disease, consider genetic testing for HNF4A variants. This is an under-recognized cause of progressive tubulopathy with a median kidney survival into the early 50s. Fourth, a new GFR estimation formula based on d-amino acids shows promise. Its major advantage is its minimal dependence on age and sex, potentially offering a more reliable diagnostic tool across diverse patient populations. And finally, for patients with IgA nephropathy, early data on the APRIL inhibitor sibeprenlimab suggest it does not impair systemic or mucosal antibody responses to vaccination or infection, a reassuring safety signal for this emerging therapy.

That's your roundup for This Week in Nephrology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.